China-based Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940) has entered into a research and development (R&D) collaboration and licensing agreement with fellow domestic entity Affinity Biopharmaceutical Co., Ltd.
Under the terms of the agreement, Affinity grants Anglikang exclusive rights for R&D, manufacturing, and commercialization of QHL-1618, a fully water-soluble small-molecule conjugate drug activated by the tumor microenvironment. The agreement encompasses the Greater China region, which includes mainland China, Hong Kong, Macau, and Taiwan, and includes an exclusive, non-transferable multi-level sublicensing patent license. In exchange, Anglikang will make an upfront payment of RMB 8 million (approximately $1.1 million) and is obligated to invest up to RMB 291 million (around $40.8 million) in pre-clinical development expenses, as well as R&D and marketing milestone payments. Additionally, Anglikang will pay a royalty of 6% to 12% on future sales.- Flcube.com
